Aims. Although aberrant DNA methylation has been described in rheumatoid arthritis (RA), no studies have interrogated this epigenetic modification in early disease.
Introduction
Rheumatoid arthritis (RA) is a common autoimmune inflammatory joint disease that affects between 0.5 and 1% of the adult population [1, 2] . Estimates of disease incidence for the UK indicate in the region of 20,000 new RA cases each year [3] , the majority of whom begin treatment with one or more disease modifying anti-rheumatic drugs. The disease is characterized by chronic inflammation and progressive destruction of synovial joint tissues, and a compelling literature now implicates alterations to the epigenome in the pathogenesis of RA. These alterations are multifactorial and include those that impact on DNA methylation, histone modifications and the expression of microRNAs [reviewed in [4] [5] [6] .
DNA methylation describes the addition of a methyl group to the nucleobase cytosine, most frequently in the context of cytosine-guanine dinucleotides (CpGs). Inappropriate methylation of these sites in promoter-associated regions is frequently associated with gene silencing, whereas in transcriptionally competent genes these sites are commonly not methylated [7] . Changes to the DNA methylome have been described in multiple cell types in patients with RA. Global levels of methylation, for example, are altered in peripheral blood mononuclear cells and lymphocytes from patients with RA [8] [9] [10] [11] . In addition, candidate gene studies also describe aberrant methylation across multiple, discrete, genes in these cell types [12] [13] [14] [15] [16] [17] [18] . Further to these studies, and in this case using genome-wide methylation arrays, we recently reported disease-associated methylation changes in multiple genes that were distinct to individual T-and B-lymphocyte populations [19] . Similar findings in the context of alterations to the epigenome are also 5 apparent in fibroblast-like synoviocytes derived from the joint [20] [21] [22] [23] [24] [25] [26] [27] , which further supports an important role for altered methylation in the pathogenesis of RA.
To date, studies of DNA methylation have been reported for patients with established RA, in many of these cases at the time of joint replacement. These patients have typically been treated over prolonged periods with a variety of disease-modifying agents, including methotrexate, a cornerstone of therapy in RA. However, a potential impact of methotrexate on DNA methylation has been suggested in RA and similar conditions [7, 28, 29] . Changes to the epigenome identified in established RA may therefore reflect, at least in part, the impact of treatment and the burden of chronic inflammation present during the evolution and progression of the disease. Thus, and as noted by others [30] , such confounders have precluded identification of methylation changes that are important drivers of disease in RA. Indeed, to our knowledge, there has been no systematic examination of DNA methylation in patients with early disease, or in those at first diagnosis and who are naïve for treatment with disease-modifying antirheumatic drugs.
In this report, and in contrast to previous studies from our own and other laboratories, we have investigated genome-wide DNA methylation in T-and B-lymphocyte populations from newly diagnosed, treatment-naïve patients with RA. Our studies in these patients mitigate the likely impact of disease evolution and of different treatment modalities and their associated sequela apparent in established disease. In this way, the identified methylation changes are likely to reflect those associated with disease development and pathogenesis.
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Patients & Methods
Patients
Genome-wide DNA methylation was investigated in 23 Caucasian patients recruited consecutively from the early synovitis clinic at the Haywood Rheumatology Centre in Stoke-on-Trent, UK, and also in a group of 11 healthy Caucasian females, the details of which we have previously reported [19] . All patients had symptomatic inflammatory arthritis suspected to be RA at presentation, and subsequently were classified with RA by a consultant rheumatologist and according to the 2010 ACR/EULAR classification criteria [31] . Demographic data and clinical characteristics for the patients are presented in Table 1 . All patients were naïve for treatment with disease modifying anti-rheumatic drugs and biological therapies. With two exceptions, all patients had active disease at recruitment based on a disease activity score with 28-joint counts (DAS28) [32 
and approximately half (44%) had high disease activity (DAS28 > 5.1). The average age of the patients and healthy control group was 58.9 ± 15.8 years and 52.6 ± 4.9 years, respectively (mean ± SD). All study participants gave written informed consent. The study was approved by the East Midlands (Derby) Research Ethics Committee.
Purification of T-and B-lymphocyte populations
Whole blood samples (35 ml, EDTA) were collected from each patient at recruitment and prior to the start of treatment. Peripheral blood mononuclear cells were prepared using density-gradient centrifugation (Histopaque-1077, Sigma Aldrich). Thereafter,
CD19
+ B-lymphocytes and CD3 + T-lymphocytes were isolated from the mononuclear cell fraction by positive selection using anti-CD19 and anti-CD3 magnetic microbeads, respectively. All isolations were performed according to the manufacturer's instructions 7 (MiniMACS® Separation System; Miltenyi Biotec). Cells were pelleted, lysed (Buffer RLT Plus; Qiagen), and homogenized (QIAShredder spin columns; Qiagen) prior to storage at -80°C. We have previously demonstrated this method of cell isolation to yield high purity T-lymphocyte (≥99%) and B-lymphocyte (≥90%) populations from patients with RA and healthy individuals alike [19, 33] .
Genome-wide DNA methylation profiling
HumanMethylation450 BeadChips (Illumina Inc.; hereafter referred to as 'array' or '450K array') were used to profile genome-wide DNA methylation at more than 480,000 CpG sites in lymphocyte populations from patients and healthy individuals.
Genomic DNA was extracted from cell lysates according to the manufacturer's instructions using an AllPrep DNA/RNA/miRNA Universal kit (Qiagen), with further concentration by ethanol-based precipitation. DNA samples were sodium bisulfite treated and hybridized to 450K arrays according to manufacturer recommended protocols (performed by Hologic Tepnel Pharma Services, UK) that we have described previously [33] . Methylation at individual CpGs is reported as a β-value [34] on a linear scale, where 0 and 1 indicate unmethylated and completely methylated sites, respectively.
Sodium bisulfite pyrosequencing
Independent quantification of methylation at array-identified candidate CpG loci was conducted by sodium bisulfite pyrosequencing. For this purpose, amplicons containing
CpGs of interest were prepared from whole-genome amplified, bisulfite-converted DNA using a touchdown PCR process, as we have described previously [33] . Oligonucleotide 8 primers for all PCR and pyrosequencing reactions were designed using PyroMark Assay Design software (Qiagen) and were specific for bisulfite-converted DNA. Primers were purchased from Biomers.net and assay details are provided in Supplementary Table 1 .
Pyrosequencing was performed according to the manufacturer's recommendations using a PyroMark Q24 instrument (Qiagen). Assays included one or more control dispensations to confirm successful bisulfite conversions. All data were analyzed using PyroMark Q24 software (v 2.0.6., build 20; Qiagen).
Data analysis
Processing and analysis of array data to determine methylation differences between treatment-naive early RA patients and healthy individuals was performed using idat files and the Bioconductor package Minfi [35] . Each array passed initial quality control assessment based on the performance of internal array controls. For each of the T-and B-lymphocyte array datasets, we excluded from analysis all probes located on the X and Y chromosomes and probes with a detection p-value > 0.01 in any one or more of the samples (n = 34 [23 patients and 11 healthy controls]). Array data were subsequently normalized using Subset-quantile Within Array Normalization (SWAN) [36] , an approach which has been shown to reduce technical variation both within and between arrays, including the technical differences observed between the two different probe types on the array [34, 37] . Following these steps, a total of 470,366 and 473,105 CpGs in T-lymphocytes and B-lymphocytes, respectively, were retained and were used in subsequent analyses.
For each of the cell types separately, the 'dmpFinder' function in Minfi was used to identify CpGs that were differentially methylated between treatment-naïve early RA patients and healthy individuals (step 1, Figure 1 ). This function performs an F-test to test the equality of means and was used with logit transformed β-values (M-values), as recommended by Du et al [38] . The false discovery rate (FDR) [39] was used to adjust for multiple testing, with adjusted p-values < 0.05 considered statistically significant.
In addition to the analysis described above, sites identified as differentially methylated in treatment-naïve early RA patients relative to healthy individuals were further examined through comparison with methylation in patients with established disease. In these cases, we used the processing and normalization procedures described above to reanalyze the 450K array data derived from a cohort of established RA patients (n = 12) that we have previously described [19] . Criteria to identify sites (a) differentially Patterns of differential methylation within and between groups were examined by hierarchical clustering using Genesis software (v1.7.6) with Euclidian distance and complete linkage criteria [40] . Further statistical analyses were performed using Stata 8.0 (Intercooled; Stata Corporation, TX, USA). P-values < 0.05 were considered significant.
Results
Genome-wide DNA methylation is altered in treatment-naïve early RA
We investigated genome-wide DNA methylation in T-and B-lymphocytes from a cohort of RA patients recruited at diagnosis and who were naïve for treatment with disease-modifying anti-rheumatic therapies. On the basis of a difference in mean β-value ≥ 0.1, and as described in Step sites shared identify between the cell types; moreover, for each of these sites, the direction of change in methylation was the same in each of the cell types.
Array data for selected CpG sites were validated by bisulfite pyrosequencing analysis.
In each case, we observed concordance between array β-values and methylation values determined by this technique, reinforcing our conclusions of differential methylation in treatment-naïve early RA patients relative to healthy controls. Figure 3 shows examples of two sites in T-lymphocytes (DUSP22 and KCNJ5) and one site in B-lymphocytes (ADAMTS17). In addition, and as previously reported by us [19, 33] , a significant correlation between the two methods was apparent across the spectrum of methylation β-values ( Figure 3A ).
Discrete methylation changes in early RA are preserved in patients with established disease
We next examined the methylation status of the 150 and 113 CpGs identified in T-and B-lymphocytes from early RA patients in a group of 12 patients with established disease that we have previously described [19] . For each of these patients, disease was of at least 5-years duration and in some cases extended to 30 years. In that study, and using the same array platform, we observed significant heterogeneity in methylation β-values across the patient samples, which we interpret may reflect the impact of disease progression or treatment modalities in these patients. We therefore assessed methylation 
Discrete methylation changes in established, but not early, disease
Finally, we determined whether methylation changes specifically associated with disease progression were also apparent. In these cases, we reasoned that these changes would be present in established disease but not in early RA patients. To this end, and as described in Step 1 of Figure 1 , we first identified those sites for which there we no statistically significant differences in methylation between treatment-naïve early RA patients and healthy individuals. We subsequently identified CpGs differentially methylated in established disease as those for which six or more patients displayed altered methylation relative to, in these cases, both the early RA and healthy control groups (step 3, Figure 1 ). Using this approach, we identified 218 CpGs in Tlymphocytes and 208 CpGs in B-lymphocytes that were aberrantly methylated and were unique to patients with established disease (green boxes, Figure 1 ; details for these sites are provided in Supplementary Tables 9 and 10) . Examples of the genes identified in T-lymphocytes (BANF2) and B-lymphocytes (PSORS1C3, PCDH12 and JRK) are presented in Figure 5 . Validation of selected genes by pyrosequencing confirmed the methylation changes observed by array in all cases (data not shown).
Discussion
The pathogenic mechanisms that drive disease in RA are not completely understood but an expanding literature implicates an important role for aberrations to the epigenome, including those which impact on the DNA methylation [4] [5] [6] [7] . However, and to our knowledge, studies focusing on DNA methylation in RA, including those from our own laboratory, have been restricted to patients with established disease and, by extension, subsequent to long-standing therapeutic intervention. These potential confounders, and others consequent to disease progression, have thus far precluded identification of aberrantly methylated loci that play an important role in the etiology and genesis of RA, as has recently been discussed in RA [30, 41] and related conditions [42, 43] .
In an attempt to address these issues, we determined genome-wide DNA methylation profiles in a cohort of newly diagnosed treatment-naïve patients with RA. Using stringent analytical and statistical criteria, we have identified novel disease-associated methylation changes in enriched T-and B-lymphocyte populations from these patients.
These changes to the epigenome in treatment-naive early disease (relative to healthy controls) target multiple genes, suggesting an important role for specific epigenetic modification in the genesis and etiology of RA. Through comparison of these new data in early RA with data from our earlier, similar work in patients with established disease [19] , we further report methylation changes present in early RA that are preserved in established disease. Similarly, we have also determined additional changes to the methylome that appear to be confined to or specific to patients with established disease.
14 The initial finding of our work was the identification of 1,951 CpGs in T-lymphocytes and 2,238 CpGs in B-lymphocytes, representing 1,216 and 1,362 genes respectively, that were differentially methylated in patients with early RA relative to healthy controls.
The overall number of CpGs we identified are similar to those reported in studies of genome-wide methylation in RA patients with established disease [25, 26] . Applying more stringent criteria to the dataset (specifically β-value differences ≥0.2), we identified 150 and 113 sites in T-and B-lymphocytes respectively that discriminated between and segregated all of the early RA patients from healthy controls. To our knowledge, we are the first to define discrete methylation signatures in RA using distinct T-and B-lymphocyte populations; interestingly, methylation patterns in Tlymphocytes have previously been shown to segregate patients from controls in other autoimmune conditions [44] .
Importantly, we found that the methylation changes defining each signature in T-and Blymphocytes were present in the majority of patients studied. Indeed, there were more than 30 sites in each cell type that showed aberrant methylation in 20 or more of the 23 patients; for some of these sites, differential methylation was apparent in all 23 of the patients investigated. Furthermore, for each individual patient, 70 or more of the 150 sites identified in T-lymphocytes, and a similar number of the 113 sites identified in Blymphocytes, were inappropriately methylated. The identification of methylation changes at these sites, and in particular those that are present in all or nearly all patients, supports a potential role for these as "drivers" of disease, rather than as "passenger" methylation events, a concept that has been described in cancer epigenetics [45, 46] . We also identified in early RA a further subset of sites (n = 44) that were differentially methylated in both the T-and B-lymphocyte populations. Moreover, for each of these sites the direction of the methylation change, hypermethylation or hypomethylation, was identical in each cell type. These sites therefore appear to reflect lymphocyte-specific, rather than cell subset-specific, methylation changes that are associated with RA.
Comparative analyses of our findings in early disease with methylation levels determined in patients with established RA led to the identification of a significant number of sites where methylation changes in treatment-naïve early RA were also apparent in established disease. Aberrant methylation at these sites was apparent in at least six of the 12 established RA patients. These findings in both early and established disease suggest that epigenetic dysregulation at these sites/genes may be important in the establishment and maintenance of the disease phenotype. Conversely, we also identified a subset of sites for which differential methylation was apparent in patients with established RA but not in those newly diagnosed with RA. These changes, again present in at least six of the 12 established RA patients, might reflect changes important in disease progression, or perhaps be consequent to disease progression, chronic inflammation [47] and responses to individual treatment modalities. They may also reflect, in part, the influence of inherent heterogeneity between patients, and may thus represent the "passenger" methylation changes discussed earlier.
Examination of the differentially methylated sites using gene ontology and pathway analysis did not identify any specific ontology/pathway terms that were significantly enriched in early RA (following adjustment for multiple testing; data not shown).
Nevertheless, amongst the sites aberrantly methylated in early RA, and in this case also in patients with established disease, we noted multiple sites within the gene for DUSP22, a protein tyrosine phosphatase for which aberrant methylation has also been described in autoimmune primary Sjögren's syndrome [42] . Sites within this gene were hypermethylated in 21 of the 23 early RA patients and in 10 of 12 patients with established disease. Amongst other actions, DUSP22 has been reported to negatively regulate STAT3 and the IL-6/STAT3 signaling pathway [48] that mediates the actions of IL-6, a key cytokine in RA [49] . A recent study has also demonstrated enhanced Tlymphocyte-mediated immune responses and spontaneous development of autoimmunity and inflammation in a DUSP22 knockout mouse model, suggesting an important suppressive role in the regulation of T-lymphocyte-mediated immunity and autoimmunity [50] . Together, these findings support a potential role for epigeneticmediated dysregulation of DUSP22 that may be important in the development and progression of RA.
The potential impact on the DNA methylome of treatment, and as a potential confounder, has been recognized by us [19, 27] and other investigators [10, 28, 30] .
Methotrexate, the first-line anti-rheumatic drug in RA [51] , has been reported to be associated with global methylation levels in inflammatory arthritis [10] , and discordance for treatment with methotrexate has been shown to significantly impact on identification of differentially methylated sites in juvenile idiopathic arthritis [28] . More recently, methotrexate has been shown to induce demethylation of the Foxp3 locus in regulatory T-lymphocytes [29], cells essential for immunological self-tolerance [52] and the development of which is known to be epigenetically controlled [53] . Given these findings, we considered it important to focus our investigation on a cohort of patients who were naïve for treatment with disease-modifying anti-rheumatic drugs, including methotrexate. In doing so, we are able to specifically exclude the likely impact of these agents from our findings and the identification of candidate CpGs/genes in this study.
The patients studied in this work were recruited consecutively from the early synovitis clinic at the hospital, with a subsequent diagnosis of RA in all cases. Through this approach we were able to study DNA methylation at first diagnosis and prior to the start of treatment. A potential caveat associated with our findings is the impact of confounding. However, and in this context, we were able to mitigate the influence of race and age, previously associated with DNA methylation [54, 55] , by studying
Caucasian subjects in whom the mean ages of early RA patients and healthy individuals were closely matched. To address the inclusion of both male and female patients, we removed prior to analysis all CpGs located on the X and Y chromosomes, as we and others have previously described [36, 56] . Furthermore, clustering analysis did not define separate clusters within the early RA group contingent on gender (data not shown). An important next step will be for the methylation signatures reported here to be replicated and verified by us and other groups in independent cohorts of newly diagnosed treatment-naïve patients.
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Conclusions
Our findings reveal, for the first time, genome-wide aberrant DNA methylation in treatment-naïve patients newly diagnosed with RA. These changes in methylation, identified using a stringent genome-wide array approach and independent of treatment, are present in individual T-and B-lymphocyte populations and define unique diseaseassociated methylation signatures. Altered methylation for a subset of the sites is also preserved in patients with established disease. These data support an important role for aberrant methylation within discrete lymphocyte populations in the development and pathogenesis of RA. This work provides an incentive for further investigations in patients with early RA, most notably, to explore the potential of these epigenetic profiles to be used to predict treatment response and inform the clinical management of this condition.
Executive Summary Background
• Compelling evidence from studies of multiple cell types describes changes to the DNA methylome in patients with rheumatoid arthritis (RA).
• Studies to date have examined patients with long-term established disease, which has precluded the identification of aberrant methylation signals associated with the etiology of RA.
• This study examined genome-wide DNA methylation in a cohort of treatment-naive patients with newly diagnosed early RA.
Patients & Methods
• Genome-wide DNA methylation profiling using HumanMethylation450 BeadChips was performed in individual T-and B-lymphocyte populations from 23 treatmentnaive patients with early RA and 11 healthy controls.
• Array data were processed and differentially methylated sites identified using Minfi.
Sites identified in early RA were further examined in patients with established disease (n = 12). Validation was conducted by bisulfite pyrosequencing.
Results
• Differential methylation in early RA was identified at 1,951 CpGs in T-lymphocytes and 2,238 CpGs in B-lymphocytes, representing 1,216 and 1,362 genes respectively.
• Sites displaying more substantial changes in methylation (≥ 0.2 difference) perfectly segregated early RA patients and healthy individuals into two discrete groups.
• A subset of sites differentially methylated in early RA showed similar methylation changes in established disease also. Conversely, sites were also identified for which methylation was altered in established, but not early, RA.
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Conclusions
• Our findings for the first time reveal genome-wide DNA methylation changes and a unique methylation signature in individual T-and B-lymphocyte populations that are present at first diagnosis in patients with RA.
• Aberrant methylation of the candidates identified is independent of confounding from disease-modifying treatments in this cohort of treatment-naïve patients.
• These data support an important role for aberrant methylation within discrete Abbreviations: bp, base pairs
